Taiwan
· Delayed Price · Currency is TWD OBI Pharma Statistics
Total Valuation
OBI Pharma has a market cap or net worth of TWD 12.93 billion. The enterprise value is 13.07 billion.
| Market Cap | 12.93B |
| Enterprise Value | 13.07B |
Important Dates
The next estimated earnings date is Tuesday, March 25, 2025.
| Earnings Date | Mar 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
OBI Pharma has 229.25 million shares outstanding. The number of shares has increased by 0.09% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 229.25M |
| Shares Change (YoY) | +0.09% |
| Shares Change (QoQ) | -0.21% |
| Owned by Insiders (%) | 0.06% |
| Owned by Institutions (%) | 6.80% |
| Float | 166.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 185.93 |
| PB Ratio | 5.47 |
| P/TBV Ratio | 5.63 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.20 |
| EV / Sales | 187.87 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -6.56 |
Financial Position
The company has a current ratio of 11.70, with a Debt / Equity ratio of 0.14.
| Current Ratio | 11.70 |
| Quick Ratio | 9.86 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.25 |
| Interest Coverage | -203.25 |
Financial Efficiency
Return on equity (ROE) is -51.23% and return on invested capital (ROIC) is -26.80%.
| Return on Equity (ROE) | -51.23% |
| Return on Assets (ROA) | -26.34% |
| Return on Capital (ROIC) | -26.80% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.01 |
| Inventory Turnover | 5.53 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.54% in the last 52 weeks. The beta is 0.99, so OBI Pharma's price volatility has been similar to the market average.
| Beta (5Y) | 0.99 |
| 52-Week Price Change | -14.54% |
| 50-Day Moving Average | 59.71 |
| 200-Day Moving Average | 64.73 |
| Relative Strength Index (RSI) | 41.92 |
| Average Volume (20 Days) | 492,858 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OBI Pharma had revenue of TWD 69.55 million and -2.11 billion in losses. Loss per share was -9.19.
| Revenue | 69.55M |
| Gross Profit | -69.38M |
| Operating Income | -2.14B |
| Pretax Income | -2.29B |
| Net Income | -2.11B |
| EBITDA | -1.99B |
| EBIT | -2.14B |
| Loss Per Share | -9.19 |
Balance Sheet
The company has 1.41 billion in cash and 492.28 million in debt, giving a net cash position of 913.24 million or 3.98 per share.
| Cash & Cash Equivalents | 1.41B |
| Total Debt | 492.28M |
| Net Cash | 913.24M |
| Net Cash Per Share | 3.98 |
| Equity (Book Value) | 3.41B |
| Book Value Per Share | 10.32 |
| Working Capital | 1.55B |
Cash Flow
In the last 12 months, operating cash flow was -1.86 billion and capital expenditures -132.69 million, giving a free cash flow of -1.99 billion.
| Operating Cash Flow | -1.86B |
| Capital Expenditures | -132.69M |
| Free Cash Flow | -1.99B |
| FCF Per Share | -8.68 |
Margins
| Gross Margin | -99.75% |
| Operating Margin | -3,071.99% |
| Pretax Margin | -3,299.57% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OBI Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.09% |
| Shareholder Yield | -0.09% |
| Earnings Yield | -16.29% |
| FCF Yield | -15.39% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |